晶方科技(603005.SH)擬推2021年限制性股票激勵計劃
格隆匯4月12日丨晶方科技(603005.SH)公佈2021年限制性股票激勵計劃(草案),擬向激勵對象授予90萬股限制性股票,涉及的標的股票種類為人民幣A股普通股,佔本激勵計劃公吿時公司股本總額的0.27%。其中首次授予72萬股,佔本激勵計劃公吿時公司股本總額的0.21%;預留18萬股,佔本激勵計劃擬授予限制性股票總數的20%,佔本激勵計劃公吿時公司股本總額的0.05%。
本計劃首次授予涉及的激勵對象共計8人,均為公司(含子公司)核心技術(業務)人員。首次授予的限制性股票價格為31.09元/股,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.